jRCT2031240210招募中不适用
Phase I investigator-initiated clinical trial of E7820 in Japanese patients with unresectable solid tumors (CIRCUS trial)
未提供0 个研究点目标入组 42 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 42
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Single Arm Study
- 干预模型
- Single Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Key inclusion criteria for both dose confirmation part and expansion part
- •Have been diagnosed with malignancy by histology or cytology (If it is conducted before registration, it may be implemented at any time.)
- •Unresectable advanced or recurrent solid tumor
- •Solid tumors refractory or intolerant to standard therapy
- •Performance Status (ECOG) is 0 or 1
- •Survival is expected to be 3 months or more from the date of enrollment
- •Age at enrollment >= 18 years
- •One or more measurable lesions on contrast enhanced CT/MRI (head/chest/abdomen/pelvis: slice thickness 5 mm or less)
- •No prior E7820 treatment.
- •Laboratory tests performed within 14 days before the enrollment date meet the following (1) to (7). However, patients should not receive Granulocyte Colony-Stimulating Factor (G-CSF) or blood transfusion within 14 days before the day of blood collection.
- •(1) Neutrophil count >= 1,500/mm3
- •(2) Platelet count >= 10 x 10000/mm3
- •(3) Hemoglobin >= 9.0 g/dL
- •(4) AST <= 75 U/L (if having hepatic metastatic disease: <=150 U/L)
- •(5) ALT <= Male: 105 U/L, Female: 57.5 U/L (if having hepatic metastatic disease: Male: 210 U/L, Female: 115 U/L)
- •(6) Total bilirubin <= 1.5 mg/dL
- •(7) Creatinine <= 1.5mg/dL
- •Percutaneous oxygen saturation (SpO2) of >= 92 % in room air in the 14 days prior to enrollment
- •For women of childbearing potential, they agree to use contraception and not to breastfeed from the informed consent, and for 30 days after the last dose of the investigational drug. For males, they agree to contraception from the informed consent, and for 30 days after the last dose of study treatment.
- •Patients who are able to comply with written informed consent and the protocol
- •Expansion part: Biliary Tract Cancer Cohort
- •In addition to the above 1) to 12), the patient has been diagnosed with unresectable or advanced/recurrent biliary tract cancer (intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma, distal cholangiocarcinoma, ampullary cancer, gallbladder cancer).
- •Expansion part: Endometrial Cancer Cohort
- •In addition to the above 1) to 12), the patient has been diagnosed with endometrial cancer that cannot be curatively resected or that has progressed or recurred.
- •Expansion part: Solid Tumor Cohort (with homologous recombination repair gene mutation)
- •In addition to 1) to 12) above, solid tumors in which homologous recombination repair gene mutations have been detected by either the cancer gene panel test or BRCA1 /2 genetic test or cancer gene panel test .
排除标准
- •Have a history of hypersensitivity reactions to sulfonamide derivatives
- •If you are receiving anticancer drugs (chemotherapy, molecular targeted therapy, immunotherapy, etc.) within 4 weeks before registration.
- •Receipt of another investigational drug or an unapproved drug within 4 weeks before registration.
- •If you have major trauma or major surgical surgery (such as surgery with general anesthesia) within 4 weeks before registration.
- •Adverse events other than hair loss and peripheral neuropathy that were judged to be related to previous treatment have not resolved below Grade 1
- •Immunosuppressive therapy with systemic or topical steroids within 2 weeks before registration (Patients who are more than or equivalent to the prednisone 10 mg/date, or patients who are scheduled to receive these therapies)
- •Pregnant or possibly pregnant or breastfeeding women
- •If you have symptomatic brain metastasis, cancer meningitis or progressive central nervous system disease (including central nervous system degenerative disease or progressive tumor). However, patients who have completed topical treatment and discontinued adrenocortical hormone therapy 4 weeks before registration are excluded. Signs (e.g., radiographic) or symptoms should be stable during the 4 weeks before registration.
- •Spine metastases requiring radiotherapy or surgical intervention
- •With pericardial, pleural, or ascitic effusion requiring treatment
- •HIV antibody, HBs antigen, or HCV-RNA is positive (but HCV-RNA is measured only if HCV antibody is positive).
- •HBs antigen-negative, HBs antibody or HBc antibody-positive, and HBV-DNA assay-positive (not excluded if undetectable)
- •Have infections requiring systemic treatment
- •If you have a history of unstable ischemic disease (ischemic heart disease, myocardial infarction, unstable heart disease, etc.) within 3 months before enrollment.
- •Antiplatelet therapy with aspirin or anticoagulation with warfarin is indicated
- •If you have a history of active hemoptysis or gastrointestinal bleeding within 3 weeks before registration.
- •Patients with active overlapping cancers (but not (1) to (3): (1) completely resected: basal cell carcinoma, stage I squamous cell carcinoma, carcinoma in situ, carcinoma in situ, and superficial bladder cancer; (2) gastrointestinal cancer curatively resected by ESD or EMR; (3) other cancer that has not recurred for more than 5 years)
- •Echocardiography shows left heart ejection fraction (LVEF) < 50%
- •There are clinically significant ECG anomalies including QT prolongation of QTc>480ms
- •Complication or history of interstitial lung disease or pulmonary fibrosis diagnosed by imaging or clinical findings
- •Psychosis or psychiatric symptoms that interfere with daily activities are concomitant, and participation in the trial is considered difficult.
- •It is evident that there has been a history of antipsychotic use or attempted suicide within the past 2 years
- •If you have a history of drug or alcohol dependence or abuse within the past 2 years.
- •Have impaired lung function requiring aggressive treatment, including oxygen
- •The investigator determines that the patient has medical or other conditions that interfere with participation in the trial.
结局指标
主要结局
-
Incidence of dose limiting toxicity
次要结局
未报告次要终点
研究者
相似试验
招募中
不适用
NCCH2213 trial (PLAS trial)jRCT203124044838
招募中
不适用
NCCH2404 trial (SAVE HEART trial)jRCTs03124071955
招募中
3 期
on-inferiority clinical trial to compare efficacy and safety of Pembrolizumab (CinnaGen Co.) versus Keytruda® in patients with metastatic Non-Small Cell Lung Cancer (NSCLC)IRCT20150303021315N29CinnaGen company295
进行中（未招募）
不适用
X01-315-02 / ?A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with 2 mg Intralesional Allovectin-7R Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects with Recurrent Metastatic Melanoma? - Allovectin-7R Immunotherapy for Metastatic Melanoma (A.I.M.M.)Recurrent metastatic melanomaMedDRA version: 9.1Level: LLTClassification code 10027481Term: Metastatic melanomaEUCTR2007-004120-21-ITVICAL INCORPORATED375
已完成
3 期
A Phase III randomized controlled clinical trial of CARBOPLATIN and PACLITAXEL(OR GEMCITABINE) alone or in combination with BEVACIZUMAB (NSC #704865, IND #7921) followed by BEVACIZUMAB and secondary cytoredutive surgery in platinum sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer.PLATINUM-SENSITIVE, RECURRENT OVARIAN, PERITONEAL PRIMARY AND FALLOPIAN TUBE CANCERJPRN-UMIN000003682Gynecologic Oncology Group1,050